FR19C1058I1 - - Google Patents

Info

Publication number
FR19C1058I1
FR19C1058I1 FR19C1058C FR19C1058I1 FR 19C1058 I1 FR19C1058 I1 FR 19C1058I1 FR 19C1058 C FR19C1058 C FR 19C1058C FR 19C1058 I1 FR19C1058 I1 FR 19C1058I1
Authority
FR
France
Prior art keywords
sub
atoms
nitrogen
formula
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR19C1058(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR19C1058I1 publication Critical patent/FR19C1058I1/fr
Application granted granted Critical
Publication of FR19C1058I2 publication Critical patent/FR19C1058I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR19C1058C 2001-07-31 2019-10-10 Methodes de mobilisation de cellules souches/embryonnaires Active FR19C1058I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US38215502P 2002-05-20 2002-05-20
EP02750370A EP1411918B1 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells
PCT/US2002/024212 WO2003011277A2 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
FR19C1058I1 true FR19C1058I1 (ru) 2019-11-22
FR19C1058I2 FR19C1058I2 (fr) 2020-10-23

Family

ID=26976666

Family Applications (2)

Application Number Title Priority Date Filing Date
FR12C0042C Active FR12C0042I1 (fr) 2001-07-31 2012-06-28 Methodes de mobilisation de cellules souches/embryonnaires
FR19C1058C Active FR19C1058I2 (fr) 2001-07-31 2019-10-10 Methodes de mobilisation de cellules souches/embryonnaires

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR12C0042C Active FR12C0042I1 (fr) 2001-07-31 2012-06-28 Methodes de mobilisation de cellules souches/embryonnaires

Country Status (29)

Country Link
US (9) US6987102B2 (ru)
EP (3) EP1411918B1 (ru)
JP (2) JP5137288B2 (ru)
KR (2) KR100996378B1 (ru)
CN (2) CN102302493B (ru)
AT (1) ATE538785T1 (ru)
AU (1) AU2002318927B2 (ru)
BE (1) BE2019C544I2 (ru)
BR (1) BRPI0211570B8 (ru)
CA (1) CA2455559C (ru)
CY (4) CY1112633T1 (ru)
DK (2) DK1411918T3 (ru)
ES (2) ES2380009T3 (ru)
FR (2) FR12C0042I1 (ru)
HK (1) HK1063005A1 (ru)
HU (1) HUP0402360A2 (ru)
IL (2) IL159312A0 (ru)
LT (2) LT2371361T (ru)
LU (2) LU92033I2 (ru)
MX (1) MXPA04000982A (ru)
NL (2) NL300537I2 (ru)
NO (4) NO336989B1 (ru)
NZ (1) NZ530169A (ru)
PL (1) PL364673A1 (ru)
PT (2) PT1411918E (ru)
RU (1) RU2309741C2 (ru)
SI (2) SI2371361T1 (ru)
WO (1) WO2003011277A2 (ru)
ZA (1) ZA200400658B (ru)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2380009T3 (es) 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
KR20040068339A (ko) 2001-12-21 2004-07-30 아노르메드 인코포레이티드 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물
WO2005007838A1 (ja) * 2003-06-27 2005-01-27 Asahi Kasei Kabushiki Kaisha 細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
WO2005017160A2 (en) * 2003-08-13 2005-02-24 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1656451A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
CA2586765A1 (en) 2004-11-05 2006-12-28 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
PT1904084E (pt) 2005-06-13 2013-07-22 Cleveland Clinic Foundation Métodos de proteção contra apoptose mediante uso de lipopéptidos
BRPI0615180A2 (pt) * 2005-08-19 2011-05-03 Genzyme Corp método para intensificar a quimioterapia
WO2007025166A2 (en) * 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
ES2497092T3 (es) * 2006-02-24 2014-09-22 Genzyme Corporation Procedimientos para el aumento del flujo sanguíneo y/o la estimulación de la regeneración de tejidos
WO2007108689A2 (en) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Method for induction of differentiation of stem and progenitor cells
US20100178271A1 (en) * 2006-08-07 2010-07-15 Genzyme Corporation Combination Therapy
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
WO2010025416A1 (en) * 2008-08-29 2010-03-04 Genzyme Corporation Cxcr4 antagonists for kidney injury
WO2011053700A1 (en) 2009-10-28 2011-05-05 Henry Ford Health System Methods to mitigate injury from radiation exposure
CN101716167B (zh) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
US20160030522A1 (en) * 2013-03-15 2016-02-04 Leonard B. Miller Combination therapy to improve soft tissue healing, fat graft healing, endochondral bone healing and osteointegration
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
WO2017049208A1 (en) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Localized delivery of anti-fugetactic agent for treatment of cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
JP6958820B2 (ja) 2015-12-14 2021-11-02 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
CA3009176A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3471716A1 (en) * 2016-06-16 2019-04-24 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
WO2018049124A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of infectious disease
EP3509609A4 (en) 2016-09-09 2021-01-20 The General Hospital Corporation HYBRID HSP PROTEIN WITH ANTI-CHEMIO-REPELLENT AGENT FOR CANCER TREATMENT
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
BR112020011186A2 (pt) * 2017-12-06 2020-11-17 Magenta Therapeutics, Inc. regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas
JP7517986B2 (ja) * 2017-12-19 2024-07-17 ジーピーシーアール セラピューティクス，インク． Ｇｐｃｒヘテロマー阻害剤及びその用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en) 2019-10-08 2024-08-13 The Regents Of The University Of California Methods and compositions for hematopoietic stem cell mobilization
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) * 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
SG49726A1 (en) 1989-10-23 1998-06-15 Nycomed Salutar Inc Compounds
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
FR2672051B1 (fr) * 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DE69309487T2 (de) 1992-11-13 1997-10-23 Univ Washington Peripheralisierung hämatopoietischer stammzellen
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd 末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
NZ507161A (en) * 1998-03-30 2003-12-19 Northwest Biotherapeutics Inc Theraupeutic and diagonistic applications based on the role of the CXCR-4 gene in tumorigenesis
WO1999065507A1 (en) * 1998-06-19 1999-12-23 The General Hospital Corporation Modulating platelet function
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
IL142094A0 (en) * 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
US6498155B1 (en) * 1998-11-17 2002-12-24 Smithkline Beecham Corporation Methods of treating thrombocytopenia
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
AU4692400A (en) * 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
CA2389545C (en) 1999-12-17 2010-08-31 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU2001258110B2 (en) 2000-05-09 2006-10-19 British Canadian Biosciences Corp. Cxcr4 antagonist treatment of hematopoietic cells
AU2001275339A1 (en) * 2000-06-05 2001-12-17 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
DK1317451T3 (da) 2000-09-15 2006-12-18 Anormed Inc Kemokinreceptorbindende heterocykliske forbindelser
MXPA03002326A (es) 2000-09-15 2003-06-06 Anormed Inc Compuestos heterociclicos de union de receptor de quimocina.
DE60137435D1 (de) 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
NZ524580A (en) 2000-09-29 2004-10-29 Anormed Inc Process for preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
MXPA03006542A (es) 2001-01-23 2003-09-22 P & G Clairol Inc Intermediarios primarios para la coloracion oxidativa del cabello.
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
ES2380009T3 (es) 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
KR20040068339A (ko) 2001-12-21 2004-07-30 아노르메드 인코포레이티드 효능이 강화된 케모카인 수용체 결합 헤테로사이클릭 화합물
DE102014206089B4 (de) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

Also Published As

Publication number Publication date
PT1411918E (pt) 2012-03-06
US20030130250A1 (en) 2003-07-10
BRPI0211570B1 (pt) 2020-01-28
ATE538785T1 (de) 2012-01-15
NO344632B1 (no) 2020-02-17
US20190216773A1 (en) 2019-07-18
EP1411918A2 (en) 2004-04-28
FR19C1058I2 (fr) 2020-10-23
US20060223180A1 (en) 2006-10-05
EP1411918B1 (en) 2011-12-28
LTPA2019018I1 (lt) 2019-12-10
WO2003011277A3 (en) 2003-05-22
US20080063624A1 (en) 2008-03-13
NO2016011I1 (no) 2016-06-10
AU2002318927B2 (en) 2007-01-04
US20110129448A1 (en) 2011-06-02
US20150246019A1 (en) 2015-09-03
LUC00139I1 (ru) 2019-11-27
LT2371361T (lt) 2019-09-10
LU92033I2 (fr) 2012-08-27
US20060193826A1 (en) 2006-08-31
US6987102B2 (en) 2006-01-17
ES2380009T3 (es) 2012-05-07
EP2371361A1 (en) 2011-10-05
US7935692B2 (en) 2011-05-03
WO2003011277A2 (en) 2003-02-13
LU92033I9 (ru) 2019-01-03
CA2455559C (en) 2012-01-10
NL301031I1 (nl) 2020-02-05
BR0211570A (pt) 2004-07-13
FR12C0042I1 (fr) 2012-08-10
CY1122199T1 (el) 2020-05-29
CN102302493A (zh) 2012-01-04
CN1561208A (zh) 2005-01-05
NO20150674A1 (no) 2015-05-27
LUC00139I2 (ru) 2021-02-10
NL301031I2 (nl) 2020-07-20
DK2371361T3 (da) 2019-08-19
LTC2371361I2 (lt) 2021-09-27
CY2019038I2 (el) 2020-05-29
DK1411918T3 (da) 2012-04-23
US20130273009A1 (en) 2013-10-17
MXPA04000982A (es) 2004-04-20
IL159312A (en) 2015-05-31
NO2020003I1 (no) 2020-03-05
HK1063005A1 (en) 2004-12-10
CN1561208B (zh) 2010-11-10
NL300537I2 (ru) 2017-02-02
PT2371361T (pt) 2019-09-10
KR20040020075A (ko) 2004-03-06
CN102302493B (zh) 2015-08-12
RU2004105961A (ru) 2005-03-20
HUP0402360A2 (hu) 2005-02-28
JP2008195730A (ja) 2008-08-28
CY2012017I2 (el) 2015-08-05
EP3632425A1 (en) 2020-04-08
NZ530169A (en) 2007-04-27
ZA200400658B (en) 2005-07-27
EP1411918A4 (en) 2007-11-14
RU2309741C2 (ru) 2007-11-10
CY2012017I1 (el) 2015-08-05
JP5137288B2 (ja) 2013-02-06
EP2371361B1 (en) 2019-08-07
KR20090130152A (ko) 2009-12-17
US20170049747A1 (en) 2017-02-23
KR100996378B1 (ko) 2010-11-25
US7897590B2 (en) 2011-03-01
CY2019038I1 (el) 2020-05-29
JP2004538303A (ja) 2004-12-24
PL364673A1 (en) 2004-12-13
ES2742730T3 (es) 2020-02-17
SI1411918T1 (sl) 2012-04-30
BE2019C544I2 (ru) 2021-07-19
NO336989B1 (no) 2015-12-14
SI2371361T1 (sl) 2019-10-30
CA2455559A1 (en) 2003-02-13
BRPI0211570B8 (pt) 2021-05-25
IL159312A0 (en) 2004-06-01
NO20040407L (no) 2004-03-19
CY1112633T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
LUC00139I1 (ru)
AP1497A (en) Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
KR930006027A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
KR920012082A (ko) Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
ES2164164T3 (es) Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
WO1994019343A3 (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
ATE258050T1 (de) Verwendung neurogen-entzuendungshemmender verbindungen und zusammensetzungen
ATE46511T1 (de) Neue 8-alkylthio-2-piperazino-pyrimido(5,4d>pyrimidine, ihre herstellung und diese verbindungen enthaltende arzneimittel.
EP1142883A4 (en) HETEROCYCLIC COMPOUNDS AND MEDICINAL COMPOSITIONS THAT CONTAIN THEM
OA09239A (fr) "Nouveaux céphèmes et procédés pour leur préparation".
WO2007106063A3 (en) Methods for increasing blood flow and/or promoting tissue regeneration
EP1057829A4 (en) Condensed pyrimidine derivatives and pharmaceutical compositions containing them
ES8605524A1 (es) Procedimiento para preparar tieno- y furo-(2,3-c)-pirroles